On October 28, 2020 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that the company plans to present at the following conferences in November (Press release, Iovance Biotherapeutics, OCT 28, 2020, View Source [SID1234569246]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Next Generation CAR and T Cell Therapies Conference (Virtual) | Nov. 2-5, 2020
Date/Time: Monday, Nov. 2 at 5:20 p.m. EST
Credit Suisse 29th Annual Virtual Healthcare Conference | Nov. 9-12, 2020
Date/Time: Monday, Nov. 9 at 1:15 p.m. EST
SITC Annual Meeting (Nov. 9-14, 2020)
Poster Presentation (Abstract #353): Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC
Authors: A Jimeno, et al.
Dates/Times: Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST
Location: Virtual Poster Hall
Stifel 2020 Virtual Healthcare Conference | Nov. 16-18, 2020
Date/Time: Wednesday, Nov. 18 at 8:00 a.m. EST
Jefferies Virtual London Healthcare Conference | Nov. 17-19, 2020
Date/Time: Thursday, Nov. 19 at 12:35 p.m. EST
Live and archived webcasts of the investor conference presentations will be available in the Investors section of the Iovance website at View Source